2026-08-23 e.701 E
時間主題
11:15 ~ 11:19
Prognostic impact of EVITA and adverse events in advanced urothelial carcinoma treated with enfortumab vedotin
講者: Satoru Taguchi 座長: Taigo Kato,
Chi-Ping Huang
11:19 ~ 11:23
Geriatric nutritional risk index as a practical biomarker for survival and severe anemia in locally advanced or metastatic UC treated with enfortumab vedotin
講者: Taku NAIKI 座長: Chi-Ping Huang,
Taigo Kato
11:23 ~ 11:27
Real-world outcomes of ICI-based combination therapies in clear cell and nonclear cell renal cell carcinoma
講者: Tomohiro Inoue 座長: Taigo Kato,
Chi-Ping Huang
11:27 ~ 11:31
Balancing oncologic safety and perioperative burden: Is kidney-sparing surgery a viable option for frail patients with high-grade UTUC?
講者: Cheng-Han Chang 座長: Taigo Kato,
Chi-Ping Huang
11:31 ~ 11:35
Prospective randomized comparison of fulldose vs low-dose SII-Onco-BCG in NMIBC
講者: Wei Tu 座長: Taigo Kato,
Chi-Ping Huang
11:35 ~ 11:39
Deferred cytoreductive nephrectomy following pembrolizumab plus lenvatinib therapy for advanced RCC
講者: Yuta Ogushi 座長: Taigo Kato,
Chi-Ping Huang
11:39 ~ 11:43
Initial experience with single-port robotic radical nephroureterectomy and bladder cuff resection
講者: Yun-Ching Su 座長: Taigo Kato,
Chi-Ping Huang
11:43 ~ 11:47
Extent, pattern, and reconstruction drive bypass use in renal cancer-associated IVC tumor thrombus surgery
講者: Yi-Hao Lin 座長: Taigo Kato,
Chi-Ping Huang